JPH07285880A - Liver function activator - Google Patents
Liver function activatorInfo
- Publication number
- JPH07285880A JPH07285880A JP6103389A JP10338994A JPH07285880A JP H07285880 A JPH07285880 A JP H07285880A JP 6103389 A JP6103389 A JP 6103389A JP 10338994 A JP10338994 A JP 10338994A JP H07285880 A JPH07285880 A JP H07285880A
- Authority
- JP
- Japan
- Prior art keywords
- alcohol
- liver function
- gpt
- liver
- treated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は、植物性蛋白質特に、と
うもろこし蛋白質より得られたペプチドを主成分とする
肝機能活性剤に関するものである。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a plant protein, and more particularly to a liver function activator containing a peptide obtained from a corn protein as a main component.
【０００２】[0002]
【従来の技術】従来から、飲酒の機会が増加すると、急
性アルコール中毒やアルコール依存症をはじめ、脂肪
肝、アルコール性肝炎や肝硬変といった肝臓障害を引き
起こすことが知られている。アルコール及びその代謝産
物であるアセトアルデヒドは、生体内の代謝系の変動要
因となり得るものであり、特にアセトアルデヒドに関し
ては、生体成分と結合したアセトアルデヒド付加物が生
体系に障害を起こすと言われている。また、近年、女性
のアルコール依存症が多くなり、妊娠中の飲酒により胎
児の発育不全、特に脳の発育不全が引き起こされ、社会
問題となるなど、アルコール依存症による大きな問題を
抱えている。日本のアルコール依存患者は約200 万人と
もいわれている。2. Description of the Related Art Conventionally, it has been known that an increase in the chance of drinking alcohol causes acute alcohol poisoning, alcohol dependence, and liver disorders such as fatty liver, alcoholic hepatitis and cirrhosis. Alcohol and acetaldehyde, which is a metabolite thereof, can be a factor that causes changes in the metabolic system in the living body, and in particular with respect to acetaldehyde, it is said that the acetaldehyde adduct combined with the biological component causes damage to the biological system. Further, in recent years, alcoholism in women has increased, and alcohol during pregnancy causes a growth failure of the fetus, especially a growth failure of the brain, which causes a social problem. It is said that there are about 2 million alcoholics in Japan.
【０００３】酒類に含まれるアルコール（エタノール、
以下単にアルコールという）は、人の心を発揚させた
り、眠気を起こす作用を有するが、アルコールの量が多
くなると、いわゆる酩酊状態にまでなってしまう。これ
は人の心を狂わす弱い一種の薬物であると考えられる。
しかしながら、アルコールはエネルギー源として栄養物
としての面も持つ。アルコールを摂取すると、大部分は
主に、肝臓に存在するアルコール脱水素酵素(ADH) によ
りアセトアルデヒドになり、さらにアセトアルデヒドは
アルデヒド脱水素酵素(ALDH)によって酢酸となる。酢酸
はそのほとんどが生体内で代謝されるといわれている。Alcohol contained in alcoholic beverages (ethanol,
(Hereinafter simply referred to as alcohol) has the effect of elevating the human mind and causing drowsiness, but when the amount of alcohol increases, it becomes so-called drunk. It is considered to be a weak drug that upsets the mind of the person.
However, alcohol also has a nutritional aspect as an energy source. When alcohol is ingested, most of it is converted into acetaldehyde mainly by alcohol dehydrogenase (ADH) existing in the liver, and acetaldehyde is converted into acetic acid by aldehyde dehydrogenase (ALDH). Most of acetic acid is said to be metabolized in vivo.
【０００４】アルコールは、空腹時の場合に胃からの吸
収が特に早く、ついで小腸でよく吸収される。空腹時に
飲酒すると、１〜２時間で完全に吸収されるといわれ、
アルコールの中毒致死量は、人の場合、血中アルコール
濃度で５mg/ml と考えられている。血液と脳のアルコー
ル濃度はほとんど同じレベルで分布されている。アルコ
ール脱水素酵素の活性は、NAD の濃度と関係があり、NA
DHの酸化を速める物質があればアルコール酸化は促進さ
れることになり、アルコール代謝を促進することにな
る。Alcohol is particularly rapidly absorbed from the stomach when fasting and is then well absorbed in the small intestine. It is said that if you drink alcohol on an empty stomach, it will be completely absorbed in 1-2 hours.
The lethal dose of alcohol poisoning is considered to be 5 mg / ml in blood for humans. Blood and brain alcohol concentrations are distributed at nearly the same level. The activity of alcohol dehydrogenase is related to the concentration of NAD,
If there is a substance that accelerates the oxidation of DH, alcohol oxidation will be promoted and alcohol metabolism will be accelerated.
【０００５】一方、アセトアルデヒドはアルコールの中
間代謝産物としての役割を果たし、頭痛、悪心、嘔吐な
どの悪酔症といった中毒症状を発現させる。慢性アルコ
ール中毒者の場合は、肝臓のアセトアルデヒド脱水素酵
素活性低下によって血中アセトアルデヒドが増加する。
この増加したアセトアルデヒドが肝障害を引き起こすと
いわれている。長期にわたるアルコール摂取による肝障
害では、ＧＯＴ、ＧＰＴが上昇することが認められてい
る。これらのＧＯＴ、ＧＰＴが減少すれば、肝機能が正
常化に向かっていると考えられる。On the other hand, acetaldehyde plays a role as an intermediate metabolite of alcohol, and causes poisoning symptoms such as headache, nausea, and vomiting such as vomiting. In the case of chronic alcoholics, blood acetaldehyde increases due to a decrease in liver acetaldehyde dehydrogenase activity.
It is said that this increased acetaldehyde causes liver damage. It has been confirmed that GOT and GPT are elevated in liver damage caused by long-term alcohol intake. If these GOT and GPT decrease, it is considered that the liver function is normalizing.
【０００６】この様な観点から、アルコール摂取の際
に、食品として容易に摂取でき、しかも血中のＧＯＴ、
ＧＰＴの上昇を抑制する作用を有するものがあれば、肝
臓障害の予防に大いに役立つものと考えられる。From this point of view, when alcohol is ingested, it can be easily ingested as food, and GOT in blood,
It is considered that if there is an agent having an action of suppressing an increase in GPT, it will be very useful for preventing liver damage.
【０００７】肝機能を活性化させ、正常化させる物質と
して、例えば、特開昭62-201820 号には、穀類、豆類の
外皮から調製された食物繊維からアルカリ抽出したヘミ
セルロースが、顕著な肝機能活性化作用を有することが
開示されている。また、特開昭63-135334 号には、穀
類、豆類の外皮から澱粉質、蛋白質等を除去して得られ
たセルロース及びヘミセルロースを主成分とする食物繊
維が同様な肝機能活性化作用を有することが開示されて
いる。As a substance that activates and normalizes the liver function, for example, in Japanese Patent Laid-Open No. 62-201820, hemicellulose obtained by alkali-extracting from dietary fiber prepared from the hulls of cereals and beans has a remarkable liver function. It is disclosed to have an activating effect. Further, in Japanese Patent Laid-Open No. 63-135334, dietary fiber mainly composed of cellulose and hemicellulose obtained by removing starches, proteins, etc. from the hulls of grains and beans has a similar liver function activating action. It is disclosed.
【０００８】また、Ｄ−ガラクトサミンを投与すると、
ＧＯＴ、ＧＰＴの上昇が抑制されることが報告されてい
る。更に、特開昭62-126126 号には、Ｌ−カルニチン又
はその塩と、トリグリセリド類と、アミノ酸、ペプチ
ド、蛋白質から選択する窒素源とを有効成分とする、Ｇ
ＯＴ、ＧＰＴの上昇を抑制する作用を有する経腸栄養剤
が開示されている。更に、特開平4-21636 号には、ポリ
オキシアルキレン類で修飾されたスーパーオキサイドジ
スムターゼ（ＳＤＯ）を有効成分とする薬剤が、肝疾患
や肝手術のために低下した肝機能を改善することが開示
されている。When D-galactosamine is administered,
It has been reported that the elevation of GOT and GPT is suppressed. Further, in JP-A-62-126126, L-carnitine or a salt thereof, triglycerides, and a nitrogen source selected from amino acids, peptides and proteins are used as active ingredients.
An enteral nutrient having an action of suppressing an increase in OT and GPT is disclosed. Furthermore, in Japanese Patent Laid-Open No. 4-21636, a drug containing a superoxide dismutase (SDO) modified with polyoxyalkylenes as an active ingredient can improve liver function or liver function that is deteriorated due to liver surgery. It is disclosed.
【０００９】[0009]
【発明が解決しようとする課題】上記のように、肝機能
活性剤として各種のものが報告されているが、とうもろ
こし蛋白質を原料とする肝機能活性剤はいまだ知られて
いなかった。As described above, various kinds of liver function activators have been reported, but liver function activators made from corn protein have not been known yet.
【００１０】したがって、本発明の目的は、アルコール
を長期にわたって摂取しても、肝障害の指標となるＧＯ
Ｔ、ＧＴＰの上昇を抑える効果、すなわち肝機能を活性
化させ、増進させ、正常化させる効果を有し、安全性が
極めて高く、安価かつ大量に供給でき、医薬品としての
みならず食品としても有用な肝機能活性剤であって、と
うもろこし蛋白質を原料とするものを提供することにあ
る。Therefore, the object of the present invention is to provide GO as an index of liver damage even if alcohol is taken for a long period of time.
It has the effect of suppressing the increase of T and GTP, that is, the effect of activating, enhancing and normalizing liver function, has extremely high safety, can be supplied in large quantities at low cost, and is useful not only as a medicine but also as a food. Another object of the present invention is to provide a hepatic function activator, which uses corn protein as a raw material.
【００１１】[0011]
【課題を解決するための手段】本発明者らは、アルコー
ルを摂取しても、肝機能障害の指標となるＧＯＴ、ＧＰ
Ｔの上昇を抑える物質、すなわち肝機能活性化作用を有
する物質を種々検索した結果、安価で最も一般的な植物
蛋白質であるとうもろこし蛋白質をアルカリプロテアー
ゼで加水分解して得られるペプチドが、特に優れたＧＯ
Ｔ、ＧＰＴの上昇抑制作用を有することを見い出し、本
発明を完成するに至った。[Means for Solving the Problems] The present inventors have found that GOT and GP are indicators of liver dysfunction even when alcohol is taken.
As a result of various searches for substances that suppress the increase in T, that is, substances that have a hepatic function activating action, peptides obtained by hydrolyzing corn protein, which is the cheapest and most common plant protein, with alkaline protease were particularly excellent. GO
They found that they have an effect of suppressing T and GPT increase, and completed the present invention.
【００１２】すなわち、本発明は、とうもろこし蛋白質
を酵素で加水分解して得られた分子量200 〜4,000 のペ
プチドを有効成分とする肝機能活性剤を提供するもので
ある。That is, the present invention provides a liver function activator containing as an active ingredient a peptide having a molecular weight of 200 to 4,000 obtained by hydrolyzing corn protein with an enzyme.
【００１３】以下、本発明について好ましい態様を挙げ
て更に詳細に説明する。本発明の肝機能活性剤の原料と
なるとうもろこし蛋白質としては、コーンスターチの製
造過程において、とうもろこしからウエットミリングを
経て得られるとうもろこし蛋白質懸濁液、例えばコーン
グルテンミール懸濁液や、コーングルテンリカーや、と
うもろこし蛋白質画分から70％の含水アルコール又はア
ルカリにて溶出してくるツエインなどが好ましく用いら
れる。Hereinafter, the present invention will be described in more detail with reference to preferred embodiments. The corn protein as a raw material of the liver function activator of the present invention, in the manufacturing process of corn starch, corn protein suspension obtained through wet milling from corn, for example, corn gluten meal suspension and corn gluten liquor, Tween and the like which are eluted from the corn protein fraction with 70% hydrous alcohol or alkali are preferably used.
【００１４】本発明の肝機能活性剤の好ましい製造方法
としては、まず、これらの原料を予め生澱粉分解酵素で
処理して澱粉を分解、除去する。好ましい態様によれ
ば、とうもろこし蛋白質の懸濁液に、水酸化ナトリウ
ム、水酸化カリウム、水酸化カルシウム等のアルカリを
添加して、pH５〜６程度に調整し、生澱粉分解酵素、例
えば「ダビアーゼ」（商品名、ダイキン工業製）を原料
固形分当たり0.02〜0.2 wt％添加して、50〜60℃にて３
〜20時間攪拌して反応させ、脱水、濾過することによ
り、澱粉を分解、除去する。In a preferred method for producing the liver function activator of the present invention, these raw materials are first treated with a raw starch degrading enzyme to decompose and remove the starch. According to a preferred embodiment, a pH of about 5 to 6 is adjusted by adding an alkali such as sodium hydroxide, potassium hydroxide or calcium hydroxide to a suspension of corn protein, and a raw starch degrading enzyme such as "Daviase" is added. (Trade name, manufactured by Daikin Industries, Ltd.) is added at 0.02 to 0.2 wt% based on the solid content of the raw material, and is added at 50 to 60 ° C.
Stir for 20 hours to react, dehydrate and filter to decompose and remove starch.
【００１５】次に、この処理物を固形分濃度５〜20wt
％、好ましくは、10〜15wt％になるように再懸濁し、こ
の懸濁液に、水酸化ナトリウム、水酸化カリウム、水酸
化カルシウム等のアルカリを添加して、好ましくはpH12
以上に調整し、50℃にてアルカリ性プロテアーゼを原料
固形分当たり0.02〜0.2wt ％添加して、50〜60℃にて３
〜20時間攪拌して反応させる。この処理によってとうも
ろこし蛋白質が適当な長さに加水分解される。Next, the treated product is treated with a solid content of 5 to 20 wt.
%, Preferably 10 to 15 wt%, and resuspended to this suspension, and an alkali such as sodium hydroxide, potassium hydroxide, calcium hydroxide, etc. is added, and preferably pH 12
After adjusting as above, 0.02 to 0.2 wt% of alkaline protease was added to the solid content of the raw material at 50 ° C, and the amount was 3 at 50 to 60 ° C.
Stir for ~ 20 hours to react. This treatment hydrolyzes the corn protein to an appropriate length.
【００１６】この場合のアルカリ性プロテアーゼとして
は、例えば掘越らの「Agric. Biol.Chem, 35(9), 1407
〜1414」に報告されている好アルカリ性細菌（Bacillu
s. No.221）由来のアルカリ性プロテアーゼ（名糖産業
株式会社製）や、好アルカリ性変異株由来の「エスペラ
ーゼ8.OL」、「サビナーゼ」（商品名、ノボ社製）など
が好適である。これらのアルカリ性プロテアーゼは、酵
素作用の最適pHが10〜12であり、耐熱性に優れており、
通常はエンド型の酵素で、遊離アミノ酸を生成しにくい
酵素である。Examples of the alkaline protease in this case include “Agric. Biol. Chem, 35 (9), 1407” by Hikoshi et al.
~ 1414 "reported by Bacillu
s. No. 221) derived from alkaline protease (manufactured by Meito Sangyo Co., Ltd.), and "esperase 8.OL" and "sabinase" (trade name, manufactured by Novo Co.) derived from an alkaliphilic mutant strain are preferable. These alkaline proteases have an optimum pH for enzyme action of 10 to 12, and have excellent heat resistance,
Usually, it is an endo-type enzyme, and it is an enzyme that hardly produces free amino acids.
【００１７】本発明の肝機能活性剤の有効成分をなすペ
プチド組成物は、例えば上記の製造方法により得られる
が、製品化に際しては、必要に応じて、最後の処理液を
濃縮し、pHを調整した後に、酸処理や、アミダーゼ、デ
アミナーゼ等の酵素処理により苦みを低減し、イオン交
換樹脂やイオン交換膜、逆浸透膜（ＲＯ膜）等により脱
塩処理し、更に活性炭処理、殺菌処理し、蒸発乾固して
粉末化することが好ましい。ただし、用途によっては、
溶液のまま用いることもできる。The peptide composition, which is an active ingredient of the liver function-activating agent of the present invention, can be obtained, for example, by the above-mentioned production method. However, when commercializing, the final treatment liquid is concentrated to adjust the pH as necessary. After adjusting, bitterness is reduced by acid treatment, enzyme treatment with amidase, deaminase, etc., desalting treatment with ion exchange resin, ion exchange membrane, reverse osmosis membrane (RO membrane), etc., further activated carbon treatment, sterilization treatment It is preferable to evaporate and dry to powder. However, depending on the application,
It can also be used as a solution.
【００１８】本発明の肝機能活性剤は、とうもろこし蛋
白質を上記のように酵素で加水分解したものからなり、
分子量分布200 〜4,000 の分子量範囲のペプチドであ
る。なお、上記ペプチドの分子量は200 〜2,000 の範囲
にあることがより好ましい。The hepatic function activator of the present invention comprises corn protein hydrolyzed with an enzyme as described above,
It is a peptide having a molecular weight range of 200 to 4,000. The molecular weight of the peptide is more preferably in the range of 200 to 2,000.
【００１９】[0019]
【作用】本発明の肝機能活性剤は、例えばアルコール摂
取の０〜30分前に経口的に少量ずつ定期的に摂取するこ
とにより、肝機能が活性化され、各種肝臓疾患に対する
治癒あるいは予防がなされる。また、本発明の肝機能活
性剤は、そのまま健康飲食品、医薬品として利用可能で
あり、飲酒の直前に飲料や錠剤等の食品として容易に摂
取することができる。The hepatic function activator of the present invention is activated orally for a small amount to periodically orally ingest small amounts, for example, 0 to 30 minutes before ingestion of alcohol, and can cure or prevent various liver diseases. Done. Further, the liver function active agent of the present invention can be used as it is as a health food and drink or a pharmaceutical product, and can be easily ingested as a food such as a drink or a tablet immediately before drinking.
【００２０】[0020]
【実施例】以下、本発明を実施例により更に詳細に説明
する。 実施例１ ウエットミリング工程から得られる蛋白質区分450Lに水
酸化ナトリウムを添加してpH5.5 に調整し、生澱粉分解
酵素「ダビアーゼ」（商品名、ダイキン工業株式会社
製）70g を添加し、50℃で５時間反応させた後、フィル
タープレスにて固液分離し、とうもろこし蛋白質のウエ
ットケーキ90Kgを得る。このウエットケーキを蒸留水35
0Lに再懸濁させ、水酸化ナトリウムを添加してpH12に調
整し、好アルカリ性細菌由来の高アルカリ性プロテアー
ゼ（名糖産業株式会社製）80g を添加し、pHを9.0 に調
整しつつ、20時間反応させる。反応液をフィルタープレ
スにて固液分離し、とうもろこし蛋白質の酵素加水分解
物を得る。EXAMPLES The present invention will now be described in more detail with reference to examples. Example 1 Sodium hydroxide was added to 450 L of the protein category obtained from the wet milling step to adjust the pH to 5.5, and 70 g of raw starch degrading enzyme "Daviase" (trade name, manufactured by Daikin Industries, Ltd.) was added to 50 After reacting at ℃ for 5 hours, solid-liquid separation is performed by a filter press to obtain 90 kg of wet cake of corn protein. This wet cake is distilled water 35
Resuspend in 0 L, adjust the pH to 12 by adding sodium hydroxide, add 80 g of highly alkaline protease derived from alkalophilic bacteria (Meito Sangyo Co., Ltd.), and adjust the pH to 9.0 for 20 hours. React. The reaction solution is subjected to solid-liquid separation with a filter press to obtain an enzymatic hydrolyzate of corn protein.
【００２１】上記加水分解物をイオン交換樹脂にて脱塩
し、吸着樹脂にて脱色・脱臭後、活性炭処理、加熱殺
菌、濃縮、乾燥して白色粉末であるペプチド、すなわち
本発明のアルコール代謝促進剤を得る。このペプチド
は、分子量分布が200 〜4,000 の範囲にあり、平均分子
量は200 〜2,000 であった。The hydrolyzate is desalted with an ion exchange resin, decolorized and deodorized with an adsorption resin, treated with activated carbon, sterilized by heating, concentrated and dried to obtain a white powder peptide, that is, the alcohol metabolism promoting of the present invention. Get the agent. This peptide had a molecular weight distribution in the range of 200 to 4,000 and an average molecular weight of 200 to 2,000.
【００２２】試験例１（長期アルコール投与ラットにお
ける肝機能活性剤のＧＯＴ、ＧＰＴに及ぼす影響） 試験動物は、脳卒中易発症高血圧自然ラット（SHR-SP)
のオス、７週令、１群５匹を用い、これらのラットを、
飼料成分以外にはアルコールを投与せず、肝機能活性
剤も投与しない群（対照区）と、飼料成分以外にアル
コールを投与し、肝機能活性剤は投与しない群（比較例
区）と、飼料成分以外にアルコールを投与し、肝機能
活性剤を摂取させた群（実施例区）とに分けた。Test Example 1 (Effect of liver function activator on GOT and GPT in rats treated with long-term alcohol) The test animals were stroke-prone spontaneously hypertensive rats (SHR-SP).
Male, 7-week-old, 1 group, 5 rats,
A group that does not administer alcohol other than feed ingredients and does not administer liver function activator (control group), a group that administers alcohol other than feed ingredients but does not administer liver function activator (comparative example group), and feed Alcohol was administered in addition to the components, and it was divided into a group (Example group) in which a liver function activator was ingested.
【００２３】飼料としては、表１に示す組成のアルコー
ル食（佐藤食品工業株式会社製）を用いた。比較例区及
び実施例区には、ラットの体重100g当たり80mg相当量の
アルコールを蒸留水で希釈し、15％アルコール水溶液と
して毎日胃ゾンデで経口投与した。また、対照区には、
上記アルコール水溶液の代わりに同量の蒸留水を同様に
経口投与した。更に、実施例区では飲料として肝機能活
性剤の５％水溶液を自由摂取させ、対照区及び比較例区
では飲料として蒸留水を自由摂取させた。As the feed, an alcoholic food (made by Sato Food Industry Co., Ltd.) having the composition shown in Table 1 was used. In Comparative Examples and Examples, 80 mg of alcohol per 100 g of rat body weight was diluted with distilled water and orally administered daily as a 15% aqueous alcohol solution using a stomach tube. In addition, in the control area,
The same amount of distilled water was orally administered instead of the above alcohol aqueous solution. Further, in the example group, a 5% aqueous solution of the liver function activator was freely ingested as a beverage, and in the control group and the comparative example group, distilled water was freely ingested as a beverage.
【００２４】こうして、各群の飼育を行いながら、飼育
開始０、１０、２０、３０日目に、１２時間の絶食期間
をおいた後、尾静脈より採血して、血中トランスアミナ
ーゼ活性（ＧＯＴ、ＧＰＴ活性）を測定した。なお、測
定には、和光純薬株式会社製の測定試薬「トランスアミ
ナーゼＣIIテスト」（商品名）を用いた。これらの結果
について、ＧＯＴを表２に、ＧＰＴを表３に、また両方
の結果をまとめて図１に示す。Thus, while feeding each group, after a 12-hour fasting period on the 0th, 10th, 20th, and 30th day after the start of feeding, blood was collected from the tail vein, and blood transaminase activity (GOT, GPT activity) was measured. In addition, the measurement reagent "transaminase CII test" (brand name) manufactured by Wako Pure Chemical Industries, Ltd. was used for the measurement. Regarding these results, GOT is shown in Table 2, GPT is shown in Table 3, and both results are summarized in FIG.
【００２５】[0025]
【表１】 [Table 1]
【００２６】[0026]
【表２】 [Table 2]
【００２７】[0027]
【表３】 [Table 3]
【００２８】表２、３の結果から、飼料成分以外にアル
コールを経口投与した群において、肝機能活性剤を投与
した実施例区では、血中トランスアミナーゼ活性（ＧＯ
Ｔ、ＧＰＴ活性）が、肝機能活性剤を投与しなかった比
較例区に比べて低く、顕著な上昇抑制効果が認められ
た。From the results shown in Tables 2 and 3, blood transaminase activity (GO) was observed in the group to which alcohol was orally administered in addition to the feed components, in the example group to which the liver function activator was administered.
(T, GPT activity) was lower than that of the comparative example group to which the liver function activator was not administered, and a remarkable increase suppressing effect was observed.
【００２９】[0029]
【発明の効果】以上説明したように、本発明の肝機能活
性剤は、毎日少量ずつ摂取することにより、アルコール
を長期にわたって摂取しても、ＧＯＴ、ＧＰＴの上昇を
抑制することができる。このように、肝機能を活性化す
るため、各種肝臓疾患に対する治癒や予防、あるいは肝
機能を正常化する作用が期待できる。また、毒性や副作
用がまったくないので、日常の食生活の中で気軽に摂取
することができる。As described above, the liver function activator of the present invention can suppress an increase in GOT and GPT even if alcohol is ingested for a long period of time by ingesting a small amount every day. In this way, since the liver function is activated, it can be expected to have an effect of healing or preventing various liver diseases or normalizing the liver function. In addition, since it has no toxicity or side effects, it can be easily taken in daily diet.
【図１】試験例１で得られた結果を示す図表である。FIG. 1 is a chart showing the results obtained in Test Example 1.
─────────────────────────────────────────────────────
─────────────────────────────────────────────────── ───
【手続補正書】[Procedure amendment]
【提出日】平成６年６月１日[Submission date] June 1, 1994
【手続補正１】[Procedure Amendment 1]
【補正対象書類名】明細書[Document name to be amended] Statement
【補正対象項目名】００２１[Correction target item name] 0021
【補正方法】変更[Correction method] Change
【補正内容】[Correction content]
【００２１】 上記加水分解物をイオン交換樹脂にて脱
塩し、吸着樹脂にて脱色・脱臭後、活性炭処理、加熱殺
菌、濃縮、乾燥して白色粉末であるペプチド、すなわち
本発明の肝機能活性剤を得る。このペプチドは、分子量
分布が２００〜４，０００の範囲にあり、平均分子量は
２００〜２，０００であった。The hydrolyzate is desalted with an ion exchange resin, decolorized and deodorized with an adsorption resin, treated with activated carbon, sterilized by heating, concentrated and dried to obtain a white powder peptide, that is, the liver functional activity of the present invention. Get the agent . This peptide had a molecular weight distribution in the range of 200 to 4,000 and an average molecular weight of 200 to 2,000.
Claims (1)
て得られた分子量200 〜4,000 のペプチドを有効成分と
する肝機能活性剤。1. A liver function activator comprising a peptide having a molecular weight of 200 to 4,000 obtained by hydrolyzing corn protein with an enzyme as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10338994A JP3764496B2 (en) | 1994-04-18 | 1994-04-18 | Alcoholic liver dysfunction inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10338994A JP3764496B2 (en) | 1994-04-18 | 1994-04-18 | Alcoholic liver dysfunction inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH07285880A true JPH07285880A (en) | 1995-10-31 |
| JP3764496B2 JP3764496B2 (en) | 2006-04-05 |
Family
ID=14352726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10338994A Expired - Fee Related JP3764496B2 (en) | 1994-04-18 | 1994-04-18 | Alcoholic liver dysfunction inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3764496B2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103710415A (en) * | 2013-12-20 | 2014-04-09 | 湖北工业大学 | Method for preparing corn peptide by using corn gluten water |
| US9259381B2 (en) | 2009-11-03 | 2016-02-16 | Isp Investments Inc. | Use of a corn peptidic hydrolyzate as an active agent stiimulating hair growth |
-
1994
- 1994-04-18 JP JP10338994A patent/JP3764496B2/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9259381B2 (en) | 2009-11-03 | 2016-02-16 | Isp Investments Inc. | Use of a corn peptidic hydrolyzate as an active agent stiimulating hair growth |
| CN103710415A (en) * | 2013-12-20 | 2014-04-09 | 湖北工业大学 | Method for preparing corn peptide by using corn gluten water |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3764496B2 (en) | 2006-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2420244B1 (en) | Lipid metabolism-improving agent | |
| CN102028093B (en) | Corn sobering-up peptide | |
| Ma et al. | Yeast proteins: The novel and sustainable alternative protein in food applications | |
| Wang et al. | Preparation of corn glycopeptides and evaluation of their antagonistic effects on alcohol-induced liver injury in rats | |
| WO1994012524A1 (en) | Protein hydrolysate derived from mucosal tissue | |
| EP0274946A1 (en) | Process for manufacturing an enzymatic protein hydrolysate rich in di- and tripeptides, for use in particular in artificial nutrition and in dietetics | |
| JPH07285881A (en) | Excitometabolic agent for alcohol | |
| JP6710098B2 (en) | Nutritional composition and dietary supplement | |
| JP4309108B2 (en) | Diabetes medicine | |
| JP3764496B2 (en) | Alcoholic liver dysfunction inhibitor | |
| KR101540004B1 (en) | Composition of Health Functional Foods for Improving of Blood sugar, Blood pressure, Blood Circulation and Cholesterol into Blood | |
| KR20020021980A (en) | Improving agent of alcoholic metabolism and decreasing agent of troubles in liver | |
| JP3979543B2 (en) | Antiallergic agent and method for producing the same | |
| JP3408739B2 (en) | Calcium absorption promoter and calcium supplement | |
| JP2003048839A (en) | PREPARATION STIMULATING iNOS ENZYME INDUCTING IMMUNOREACTIVE NO SYNTHESIS AND METHOD FOR PRODUCING THE PREPARATION | |
| JP2010100530A (en) | Anti-obestic agent | |
| WO2005120541A1 (en) | Process for producing protein having its antihypertensive activity enhanced | |
| JP3448344B2 (en) | Peptide composition | |
| JP2000201651A (en) | Production of gamma-aminobutyric acid and food containing gamma-aminobutyric acid | |
| US20080227869A1 (en) | Substituted nitrobenzene derivatives as pharmaceutical and other uses thereof | |
| WO2022224776A1 (en) | Lipid decrease promoter | |
| KR101168673B1 (en) | Soju containing chitosan and preparing method thereof | |
| KR20030015537A (en) | Process for preparing a peptide lowering blood lipid level | |
| EP0398525A1 (en) | Compositions, containing inositol phosphate, preparation and uses | |
| RU2366263C2 (en) | Broth with preventive properties, containing protein hydrolisate and protein hydrolisate production method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050614 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050812 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20050812 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051011 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051121 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20051227 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060120 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100127 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100127 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100127 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110127 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110127 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120127 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120127 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130127 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130127 Year of fee payment: 7 |
|
| LAPS | Cancellation because of no payment of annual fees |